Announcing Courage has received a $7.8M seed investment round to progress our obesity and anorexia programs
The investment will enable Courage Therapeutics to complete essential testing and development to advance its drug candidates to clinical trials. The company’s two drug-development programs aim to address obesity and restrictive eating disorders, such as anorexia nervosa and cachexia, by targeting neural circuits in the brain known as the central melanocortin system.